Frontlight ResearchEarly access
CompletedNo phase
Liver Fibrosis Risk With Methotrexate Exposure
Key facts
- Who runs it
- Vastra Gotaland Region
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 200 people enrolled
- Started
- 1 Jun 2023
- Ended
- 30 Apr 2025
- Type of study
- Observational, 2 groups
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients with a diagnosis of RA or PsA followed at the Department of Rheumatology at Sahlgrenska University Hospital, Gothenburg, Sweden
- Age 18-70
- Ongoing treatment with methotrexate
- Available data of MTX initiation date, treatment duration and cumulative exposure
Who cannot take part
- other rheumatic diseases than RA och PsA
- known chronic liver disease
- active hepatitis B or C infection
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
METOHEP is a cross-sectional observational study with the aim to study associations of methotrexate (MTX) exposure and metabolic characteristics with non-invasive liver stiffness and steatosis in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
The 2 groups in the trial
- Patients with RA and PsA
Patients receiving MTX at assessment, for whom MTX initiation, current weekly dose, treatment duration and cumulative exposure could be established.
- Reference group
Patients with RA or PsA with no prior methotrexate exposure
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comprehensive Assessment of Risk for Liver Fibrosis in Long-term Methotrexate Therapy (METOHEP)
- Record updated
- 10 November 2026